Lexaria Bioscience Corp. (LEXX)
| Bid | 1.07 |
| Market Cap | 23.06M |
| Revenue (ttm) | 523.28K |
| Net Income (ttm) | -7.71M |
| EPS (ttm) | -0.5 |
| PE Ratio (ttm) | -2.63 |
| Forward PE | -4.38 |
| Analyst | Strong Buy |
| Ask | 1.39 |
| Volume | 231,522 |
| Avg. Volume (20D) | 177,537 |
| Open | 1.45 |
| Previous Close | 1.47 |
| Day's Range | 1.27 - 1.48 |
| 52-Week Range | 1.27 - 6.85 |
| Beta | 0.96 |
About LEXX
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time ...
Analyst Forecast
According to 2 analyst ratings, the average rating for LEXX stock is "Strong Buy." The 12-month stock price forecast is $9.5, which is an increase of 623.20% from the latest price.
2 weeks ago · accessnewswire.com
Lexaria Granted Two New DehydraTECH Patents for Treatment of EpilepsyAdditions broaden DehydraTECH patent suite for Epilepsy KELOWNA, BC / ACCESS Newswire / February 11, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global ...
3 weeks ago · accessnewswire.com
Lexaria Biodistribution Study For DehydraTECH GLP-1 is UnderwayWorld's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BC / ACCESS Newswire / February 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" ...
2 months ago · https://thefly.com
Lexaria Bioscience's Phase 1b study starts patient dosing, says H.C. WainwrightH.C. Wainwright reiterates a Buy rating and $10 price target on Lexaria Bioscience shares after the company announced that the Phase 1b 12-week chronic study in Australia has started patient dosing as...